Sylvan C. Baca, Ph.D.
Affiliations: | 2013 | Biology: Medical Sciences, Division of | Harvard University, Cambridge, MA, United States |
Area:
Molecular Biology, Bioinformatics BiologyGoogle:
"Sylvan Baca"Parents
Sign in to add mentorLevi A. Garraway | grad student | 2013 | Harvard | |
(The landscape of somatic mutations in primary prostate adenocarcinoma.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Baca SC, Seo JH, Davidsohn MP, et al. (2023) Liquid biopsy epigenomic profiling for cancer subtyping. Nature Medicine |
Spisak S, Tisza V, Nuzzo PV, et al. (2023) Author Correction: A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus. Nature Communications. 14: 6623 |
Spisak S, Tisza V, Nuzzo PV, et al. (2023) A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus. Nature Communications. 14: 5118 |
Moon I, LoPiccolo J, Baca SC, et al. (2023) Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. Nature Medicine. 29: 2057-2067 |
Gusev A, Moon I, LoPiccolo J, et al. (2023) Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patients. Research Square |
Kneppers J, Severson TM, Siefert JC, et al. (2022) Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential. Nature Communications. 13: 7367 |
De Sarkar N, Patton RD, Doebley AL, et al. (2022) Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes. Cancer Discovery |
Shi X, Day A, Bergom HE, et al. (2022) Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer. Npj Precision Oncology. 6: 80 |
Baca SC, Singler C, Zacharia S, et al. (2022) Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation. Nature Genetics |
Linder S, Hoogstraat M, Stelloo S, et al. (2022) Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence. Cancer Discovery |